Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glucose-lowering compound magnolol health care product

A technology of honokiol and health care products, applied in the field of hypoglycemic health care products, can solve the problems of slow hypoglycemic and lipid-lowering effect, insignificant curative effect, single action mechanism, etc., and achieves the effects of high safety and remarkable curative effect.

Inactive Publication Date: 2010-03-17
孙长颢
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The present invention provides a hypoglycemic compound magnolol health care product in order to solve the problems of single mechanism of action, insignificant curative effect and slow hypoglycemic and lipid-lowering effect in existing magnolia bark preparations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glucose-lowering compound magnolol health care product
  • Glucose-lowering compound magnolol health care product
  • Glucose-lowering compound magnolol health care product

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0011] Specific Embodiment 1: In this embodiment, the hypoglycemic compound magnolol health care product consists of 10-15 mg / kg BW of magnolol, 20-30 μg / kg BW of chromium picolinate and 3-7 mg / kg BW of auxiliary materials Composition; wherein the auxiliary materials are composed of 0.2-0.7 parts by weight of aspartame, 2.5-6.0 parts by weight of micropowder silica gel and 0.2-0.7 parts by weight of pineapple essence.

[0012] In the state of obesity, the ability of adipose tissue to regulate the amount of fatty acids released into the blood by reducing the release of free fatty acids (FFA) and increasing the clearance of triglycerides is impaired, and the oxidation ability of various tissues to free fatty acids is reduced, resulting in excessive The accumulation of FFA in the liver, skeletal muscle and pancreatic tissue may cause insulin resistance and pancreatic β-cell failure, that is, lipotoxicity. If the FFA level in patients with type 2 diabetes can be reduced, insulin re...

specific Embodiment approach 2

[0016] Specific embodiment two: The difference between this embodiment and specific embodiment one is that the hypoglycemic compound magnolol health care product consists of magnolol of 11~14mg / kg BW, chromium picolinate of 22~28 μg / kg BW and The composition of excipients is 4~6mg / kg·BW. Others are the same as in the first embodiment.

specific Embodiment approach 3

[0017] Specific embodiment three: The difference between this embodiment and specific embodiment one is that the hypoglycemic compound magnolol health product is composed of magnolol of 12mg / kg BW, chromium picolinate of 24 μg / kg BW and 5mg / kg BW Excipient composition of BW. Others are the same as in the first embodiment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A glucose-lowering compound magnolol health care product relates to a glucose-lowering health care product which solves the problems of single action mechanism, indistinctive curative effect and slowglucose-lowering and lipid lowering functions in the existing magnolia officinalis preparation. The glucose-lowering compound magnolol health care product consists of magnolol, chromium picolinate andauxiliary materials, comes into play by enhancing a plurality of functions such as insulin sensitivity, antioxidation and the like; and tests show that the product has obvious effect in lowering ratblood sugar of type 2 diabetes mellitus, can obviously improve rat glucose intorlerance of type 2 diabetes mellitus, and has obvious effect in lowering rat blood-lipid of the type 2 diabetes mellitus.The glucose-lowering compound magnolol health care product has obvious curative effect, high safety, and no side-effect and is applicable to the adjuvant therapy of type 2 diabetes mellitus patients.

Description

technical field [0001] The invention relates to a hypoglycemic health care product. Background technique [0002] Diabetes is divided into type 1 diabetes and type 2 diabetes. In 2002, there were about 20 million people with diabetes in my country. It is estimated that by 2030, the population with diabetes in my country will exceed 40 million, and type 2 diabetes accounts for more than 90% to 95% of the total number of diabetes. Very important. Type 2 diabetes is insulin resistance with relative insufficient insulin secretion, or insulin secretion deficiency with or without insulin resistance, which can damage multiple organ systems such as the cardiovascular system, eyes, kidneys, and nerves. [0003] At present, the treatment for diabetes mainly includes diet therapy, exercise therapy and drug therapy. Diet and exercise therapy are suitable for all stages of diabetes development, but due to its slow curative effect, drug therapy should also be used for more serious diabe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A23L1/29A23L1/30A23L33/105
Inventor 孙长颢李颖宁华牛玉存李松涛
Owner 孙长颢
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com